Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.44NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XBB.1.44NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.44NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.26NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5.26NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
XBB.1.5.26NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.26NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.26NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBB.1.5.26NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XBB.1.5.26NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.5.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GN.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
GN.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
GN.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GN.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GN.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
GN.3NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
GN.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
GN.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FW.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
FW.2NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
FW.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FW.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FW.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
FW.2NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.461NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.461NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.461NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.461NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.461NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.486NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.486NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.486NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.486NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.486NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.486NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.486NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.486NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.3NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.603NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.603NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.603NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.603NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used